RNS Number : 3719D
Genus PLC
28 June 2021

For Immediate Release

28 June 2021

Genus plc
('Genus', or the 'Company')

PIC AND SERGAL ENTER INTO STRATEGIC RELATIONSHIP

Genus plc (LSE: GNS), a leading global animal genetics company, announces that its porcine genetics business, PIC, has entered into a strategic relationship with the shareholders of Sergal Gestió Ramadera, S.L., a leading Spanish porcine genetic distributor. The relationship will become effective in the third quarter of 2021.

Sergal is a leading porcine distributor in Spain and its high quality supply chain, commitment to customer service and innovative culture make it an ideal partner to enhance the distribution of PIC's elite porcine genetics in the Spanish and European markets. This strategic relationship will support pork producers across Europe by combining PIC's elite genetics with Sergal's focus on customer service and deep knowledge of the market. The commercial terms of the relationship remain confidential.

Under the strategic relationship, PIC will acquire Sergal's semen supply chain, which will be integrated into PIC's European gene transfer network, and certain other commercial assets. The parties will continue to collaborate to ensure an ongoing focus on customer service and the delivery of PIC's elite genetics and related services.

Within the EU, the pig herd in Spain continues to expand year on year due to strong domestic demand and a focus on exports. Spain continues to be one of the key global pork markets exporting to China.

Commenting on the strategic relationship, Albert Noguera and Sergi Armengol - Sergal's founders and owners - said: "*When we created the company our vision was to provide the best genetics to Spanish producers. This new relationship with PIC will help us further expand our offering and services and to realize our vision.*"

Jürgen Kramer, General Manager for PIC Europe added: "*Spain is a key market in global pig production with tremendous opportunity for growth. This strategic relationship represents a further milestone in PIC's European strategy, where we continue to make significant investments given the long-term potential of the region.*"

Genus Tel: +44 (0)1256 347100

Stephen Wilson, Chief Executive

Alison Henriksen, Chief Financial Officer

Buchanan Tel: +44 (0)207 466 5000

Charles Ryland /Chris Lane

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals

with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASELFLAEFSEDM